Celsion (CLSN) is out with some upbeat ThermoDox commentary, saying the HEAT study's lead...

|About: Celsion Corporation (CLSN)|By:, SA News Editor

Celsion (CLSN) is out with some upbeat ThermoDox commentary, saying the HEAT study's lead European principal investigator Riccardo Lencioni has made two presentations discussing what he says are "post-hoc data that indicate ThermoDox may provide potential for clinically relevant improved progression free survival (PFS) and Overall Survival (OS) outcomes." Shares +14.75% premarket. (Previous: SA contributor spars with CLSN over HEAT study)